Gene

EGFR

epidermal growth factor receptor

Explore in graph →CI-GENE-00044375HGNC:3236 ENSG00000146648 NCBI 1956 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (644)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 401–450 of 644 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR L8611
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports

Cohorts

Alteration frequency by cohort (195)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved195 cohort rows (showing 45, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Endometrial Cancer (MSK, Cancer Discovery 2023) ucec_ancestry_cds_msk_2023	Endometrial Carcinoma	Ssm

Literature

Linked publications (141)

25 per page, newest first.

pubmedPublishedShowing 26–50 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.
· Onco Targets Ther · 2014 · PMID 24729716 · validated civic_curation pubmed
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
· Clin Cancer Res · 2006 · PMID 16818686 · validated civic_curation pubmed
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
· J Clin Oncol · 2007 · PMID 17538160 · validated civic_curation pubmed
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

EGFR L861Q7
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted	EID10070 In an in vitro study, EGFR ectodomain missense mutants (T263P, A289V, G598V, L861Q) were expressed in human immortalized astrocytes and BaF3 cells. Phosphorylation was measured via immunoblot. All ect… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic
Afatinib	Esophageal Squamous Cell CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	4	submitted	EID9679 This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID4514 In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
〃	High-Grade Glioma, NOS	Predictive	D	Supports Sensitivity Response	3	accepted	EID4299 In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID3802 In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5826 EGFR L861Q was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Osimertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID7858 In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who … (full text at CIViC) PMID 31825714 · Cho et al., 2020 · Open in CIViC	civic

EGFR L861Q7

(functional)

—UNRESOLVED

Functional

Supports Gain Of Function

submitted

EID10070

In an in vitro study, EGFR ectodomain missense mutants (T263P, A289V, G598V, L861Q) were expressed in human immortalized astrocytes and BaF3 cells. Phosphorylation was measured via immunoblot. All ect… (full text at CIViC)

PMID 17177598 · Lee et al., 2006 · Open in CIViC

EGFR M766Q3
Neratinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID7389 L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors. Modeling suggested that EGFR M766Q could disrupt osi… (full text at CIViC) PMID 31254668 · Castellano et al., 2019 · Open in CIViC	civic
Osimertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	3	submitted	EID7388 A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acqui… (full text at CIViC) PMID 31254668 · Castellano et al., 2019 · Open in CIViC	civic
Poziotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID7390 L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors. Modeling suggested that EGFR M766Q could disrupt osi… (full text at CIViC) PMID 31254668 · Castellano et al., 2019 · Open in CIViC	civic

EGFR Mutation26
(prognostic)	Lung Adenocarcinoma	Prognostic	B	Supports Better Outcome	4	accepted	EID1701 In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001). PMID 22810899 · Johnson et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Prognostic	B	Supports Better Outcome	3	accepted	EID3792 Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease … (full text at CIViC) PMID 21969500 · Brugger et al., 2011 · Open in CIViC	civic
〃	Cholangiocarcinoma	Prognostic	B	Supports Poor Outcome	2	submitted	EID10359 In a study of 137 biliary tract carcinomas, 13 patients were identified to have EGFR variants in exons 18-21 (no other exons were evaluated). EGFR variants were associated with worse survival in univa… (full text at CIViC) PMID 24372748 · Chang et al., 2014 · Open in CIViC	civic
Afatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID1728 In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with fir… (full text at CIViC) PMID 27083334 · Park et al., 2016 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID2153 In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID12780 An in vitro study transformed Ba/F3 murine cells (IL-3 dependent lymphocyte model) with one of five uncommon EGFR mutations: Del18 (delE709_T710insD), E709K, G719A, S768I, and L861Q. The response to c… (full text at CIViC) PMID 40940797 · Oiki et al., 2025 · Open in CIViC	civic
Amivantamab + LazertinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID12928 This clinical study focuses on 105 participants included in the CHRYSALIS-2 Cohort (Cohort C), examining the treatment outcome of atypical EGFR mutation non-small cell lung cancer (NSCLC) to a combine… (full text at CIViC) PMID 41325571 · Tomasini et al., 2025 · Open in CIViC	civic
Cytoreductive Surgery + Hyperthermic Intraperitoneal ChemotherapyCombination	Peritoneal Mesothelial NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID5923 25 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR muta… (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC	civic
Datopotamab Deruxtecan	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12523 TROPION-Lung01 (NCT04656652) was a global, randomized, open-label phase III trial of 604 patients with previously treated advanced NSCLC comparing datopotamab deruxtecan (Dato-DXd) with docetaxel. Dat… (full text at CIViC) PMID 39250535 · Ahn et al., 2025 · Open in CIViC	civic
Datopotamab Deruxtecan Regimen	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12522 Phase II trial (NCT04484142) of Dato-DXd 6 mg/kg every 3 weeks in 137 heavily pretreated patients with advanced NSCLC harboring actionable genomic alterations (57% EGFR-mutant; 51% with prior brain me… (full text at CIViC) PMID 39761483 · Sands et al., 2025 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID7024 In this open-label, randomised, phase 3 trial at 22 centres in China, patients with stage IIIB or IV NSCLC who had exon 19 deletion or exon 21 L858R point mutation, and who had not received previous s… (full text at CIViC) PMID 21783417 · Zhou et al., 2011 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID3794 In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 pati… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC	civic
〃	Malignant Lung Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID3864 In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib, patients whose tumors harbored EGFR mutations (n=3) had a higher 12-week progression-free survival rate compa… (full text at CIViC) PMID 22025157 · Ramalingam et al., 2011 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	4	accepted	EID4201 In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, E… (full text at CIViC) PMID 21969500 · Brugger et al., 2011 · Open in CIViC	civic
Futuximab/Modotuximab Mixture	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	rejected	EID1056 In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and p… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	accepted	EID1937 This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	accepted	EID2148 In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR… (full text at CIViC) PMID 19692680 · Mok et al., 2009 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID2559 Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 pati… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID3016 In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free surviv… (full text at CIViC) PMID 20038723 · Douillard et al., 2010 · Open in CIViC	civic
〃	Malignant Lung Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID2939 In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I7… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Does Not Support Reduced Sensitivity	3	submitted	EID6187 In a Japanese phase III study, lung adenocarcinoma patients with one or more of any mutation in their EGFR gene were treated with either Erlotinib or Gefitinib EGFR tyrosine kinase inhibitors to demon… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC	civic
Afatinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	submitted	EID6465 Three major drug resistance mutations, namely L718Q, L844V, and C797S were identified in EGFR and caused resistance to both WZ4002 and CO-1686. In contrast, only EGFR C797S caused AZD9291 resistance.… (full text at CIViC) PMID 25948633 · Ercan et al., 2015 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID2053 In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patien… (full text at CIViC) PMID 21258250 · Ludovini et al., 2011 · Open in CIViC	civic
EGFR Tyrosine Kinase Inhibitor Therapy + MetforminCombination	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID12074 In this trial, 139 patients with lung adenocarcinomas harbouring EGFR activating mutations were randomly assigned to two groups to receive either EGFR-TKIs alone (n = 70) or a combination of TGFR-TKIs… (full text at CIViC) PMID 31486833 · Arrieta et al., 2019 · Open in CIViC	civic
Gefitinib + PemetrexedCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7650 A phase 2 study was conducted to compare treatment with pemetrexed and gefinitib (P+G) versus gefinitib monotherapy for a population of 195 East Asian non-squamous NSCLC patients with EGFR mutations (… (full text at CIViC) PMID 31605797 · Yang et al., 2020 · Open in CIViC	civic
Cisplatin + Pemetrexed + SintilimabCombination	Lung Carcinoma	Predictive	B	Supports Sensitivity Response	4	submitted	EID13098 In the randomized, double-blind phase III ORIENT-31 trial, patients with EGFR-mutated, nonsquamous non-small-cell lung cancer that had progressed following EGFR tyrosine kinase inhibitor therapy were … (full text at CIViC) PMID 37156249 · Lu et al., 2023 · Open in CIViC	civic

EGFR N771delinsGY2
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID12420 In an in vitro study, MCF-7 cells expressing the EGFR N771delinsGY (N771GY) mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 50 nM. In comparison… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	—	submitted	EID4671 In a stage III lung adenocarcinoma patient of African-American descent with EGFR N771>GY mutation, EGFR N771>GY was reported to be resistant to erlotinib treatment. The patient was treated with 4 cycl… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic